15 results on '"Balakirouchenane, David"'
Search Results
2. A rapid LC-MS/MS method for the simultaneous quantification of ivacaftor, lumacaftor, elexacaftor, tezacaftor, hexyl-methyl ivacaftor and ivacaftor carboxylate in human plasma
- Author
-
Zheng, Yi, Rouillon, Steeve, Khemakhem, Mohamed, Balakirouchenane, David, Lui, Gabrielle, Abdalla, Seef, Sanoufi, Mohammed Rohi, Sauvaitre, Lucie, Thebault, Laure, Hirt, Déborah, Treluyer, Jean-Marc, Gana, Inès, Benaboud, Sihem, and Froelicher-bournaud, Léo
- Published
- 2024
- Full Text
- View/download PDF
3. Hydroxychloroquine sulfate: A novel treatment for lipin-1 deficiency?
- Author
-
Renard, Perrine, Caccavelli, Laure, Legendre, Antoine, Tuchmann-Durand, Caroline, Balakirouchenane, David, Blanchet, Benoit, Narjoz, Céline, Straube, Marjolène, Hubas, Arnaud, Garros, Alexa, Mention, Karine, Bednarek, Nathalie, Goudin, Nicolas, Broissand, Christine, Schlatter, Joel, Cisternino, Salvatore, Cagnard, Nicolas, van Endert, Peter, Diana, Julien, de Calbiac, Hortense, and de Lonlay, Pascale
- Published
- 2023
- Full Text
- View/download PDF
4. Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management
- Author
-
Bellesoeur, Audrey, Gataa, Ithar, Jouinot, Anne, Mershati, Sarah El, Piketty, Anne-Catherine, Tlemsani, Camille, Balakirouchenane, David, Monribot, Anthia, Vidal, Michel, Batista, Rui, de Percin, Sixtine, Villeminey, Clémentine, Alexandre, Jérôme, Goldwasser, François, Blanchet, Benoit, Boudou-Rouquette, Pascaline, and Thomas-Schoemann, Audrey
- Published
- 2021
- Full Text
- View/download PDF
5. Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.
- Author
-
Balakirouchenane, David, Seban, Romain, Groussin, Lionel, Puszkiel, Alicja, Cottereau, Anne Ségolène, Clerc, Jerome, Vidal, Michel, Goldwasser, Francois, Arrondeau, Jennifer, Blanchet, Benoît, and Huillard, Olivier
- Subjects
- *
IODINE isotopes , *THYROID cancer , *DRUG utilization , *ELECTRONIC health records , *PHARMACOKINETICS , *PHARMACODYNAMICS - Abstract
Background: BRAF and MEK inhibitors are cornerstones of the redifferentiation strategy in metastatic radioactive iodine (RAI)-resistant mutant thyroid cancers. We explored the exposure–toxicity relationship for dose-limiting toxicity (DLT) onset in patients treated with dabrafenib and/or trametinib and investigated whether plasma exposure was associated with RAI reuptake. Methods: We conducted a retrospective monocentric study in which we reviewed the electronic medical records of patients treated in our institution with a tumor redifferentiation strategy, for whom plasma concentration of dabrafenib, its active metabolite hydroxy-dabrafenib, and trametinib was measured. Trough concentrations (Cminpred) and total plasma drug exposure (area under the curve, AUC) of dabrafenib (AUCDAB), hydroxy-dabrafenib (AUCOHD), and trametinib (AUCTRA) were estimated. Results: Of the 22 patients treated in a redifferentiation strategy between March 2014 and December 2021, 15 were included in this study. A dabrafenib- or trametinib-related DLT was experienced by 8 (62%) and 9 (64%) patients, respectively. Patients who experienced a trametinib-related DLT exhibited a significantly higher last AUCTRA than the average AUCTRA of patients who had no DLT (390, IQR: 67 vs. 215, IQR: 91 ng/mL·h−1, respectively; p = 0.008). Patients who experienced a dabrafenib-related DLT had a higher AUCDAB than observed in other patients (9265 ng/mL·h−1 vs. 6953 ng/mL·h−1, respectively; p = 0.09). No clinical and demographical characteristic was associated with the DLT onset. Overall, 9 of 15 (60%) patients demonstrated tumor redifferentiation. Patients in whom RAI reuptake was achieved had significant lower AUCDAB (6990 ng/mL·h−1 vs. 9764 ng/mL·h−1, p = 0.014; respectively) compared with patients who did not. Moreover, the relative exposure ratio of AUCOHD/DAB was significantly higher in patients who achieved RAI reuptake (1.11 vs. 0.71, respectively; p = 0.0047). Conclusions: Our data suggest a relationship between DLT onset and trametinib plasma exposure, as well as an association between achievement of RAI reuptake and dabrafenib plasma exposure (AUC and ratio of AUCOHD/DAB). These data imply that the use of plasma drug monitoring could be helpful in guiding clinical practice in redifferentiation treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. LC-MS/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing’s Syndrome
- Author
-
Balakirouchenane, David, Vasseur, Axelle, Bonnet-Serrano, Fidéline, Choi, Minna, Khoudour, Nihel, Puszkiel, Alicja, Groussin, Lionel, Vidal, Michel, Declèves, Xavier, Bertherat, Jérôme, and Blanchet, Benoit
- Published
- 2023
- Full Text
- View/download PDF
7. Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry
- Author
-
Balakirouchenane, David, Khoudour, Nihel, Guégan, Sarah, Kramkimel, Nora, Franck, Nathalie, Rodier, Thomas, Goldwasser, François, Dupin, Nicolas, Aractingi, Selim, Vidal, Michel, and Blanchet, Benoit
- Published
- 2021
- Full Text
- View/download PDF
8. Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma.
- Author
-
Isberner, Nora, Gesierich, Anja, Balakirouchenane, David, Schilling, Bastian, Aghai-Trommeschlaeger, Fatemeh, Zimmermann, Sebastian, Kurlbaum, Max, Puszkiel, Alicja, Blanchet, Benoit, Klinker, Hartwig, and Scherf-Clavel, Oliver
- Subjects
GENETIC mutation ,MELANOMA ,PROTEIN kinase inhibitors ,SERUM ,BLOOD collection ,CANCER patients ,DRUG monitoring ,LONGITUDINAL method - Abstract
Simple Summary: In melanoma patients treated with dabrafenib and trametinib, dose reductions and treatment discontinuations related to adverse events (AE) occur frequently. However, the associations between patient characteristics, AE, and exposure are unclear. Our prospective study analyzed serum (hydroxy-)dabrafenib and trametinib exposure and investigated its association with toxicity and patient characteristics. Additionally, the feasibility of at-home sampling of capillary blood was assessed, and a model to convert capillary blood concentrations to serum concentrations was developed. (Hydroxy-)dabrafenib or trametinib exposure was not associated with age, sex, body mass index, or AE. Co-medication with P-glycoprotein inducers was associated with lower trough concentrations of trametinib but not (hydroxy-)dabrafenib. The applicability of the self-sampling of capillary blood was demonstrated. Our conversion model was adequate for estimating serum exposure from micro-samples. The monitoring of dabrafenib and trametinib may be useful for dose modification and can be optimized by at-home sampling and our new conversion model. Patients treated with dabrafenib and trametinib for BRAF
V600 -mutant melanoma often experience dose reductions and treatment discontinuations. Current knowledge about the associations between patient characteristics, adverse events (AE), and exposure is inconclusive. Our study included 27 patients (including 18 patients for micro-sampling). Dabrafenib and trametinib exposure was prospectively analyzed, and the relevant patient characteristics and AE were reported. Their association with the observed concentrations and Bayesian estimates of the pharmacokinetic (PK) parameters of (hydroxy-)dabrafenib and trametinib were investigated. Further, the feasibility of at-home sampling of capillary blood was assessed. A population pharmacokinetic (popPK) model-informed conversion model was developed to derive serum PK parameters from self-sampled capillary blood. Results showed that (hydroxy-)dabrafenib or trametinib exposure was not associated with age, sex, body mass index, or toxicity. Co-medication with P-glycoprotein inducers was associated with significantly lower trough concentrations of trametinib (p = 0.027) but not (hydroxy-)dabrafenib. Self-sampling of capillary blood was feasible for use in routine care. Our conversion model was adequate for estimating serum PK parameters from micro-samples. Findings do not support a general recommendation for monitoring dabrafenib and trametinib but suggest that monitoring can facilitate making decisions about dosage adjustments. To this end, micro-sampling and the newly developed conversion model may be useful for estimating precise PK parameters. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer.
- Author
-
Rodier, Thomas, Puszkiel, Alicja, Cardoso, Evelina, Balakirouchenane, David, Narjoz, Céline, Arrondeau, Jennifer, Fallet, Vincent, Khoudour, Nihel, Guidi, Monia, Vidal, Michel, Declèves, Xavier, Csajka, Chantal, Alexandre, Jérôme, Cadranel, Jacques, Fabre, Elizabeth, Wislez, Marie, Goldwasser, François, and Blanchet, Benoit
- Subjects
NON-small-cell lung carcinoma ,EPIDERMAL growth factor receptors ,OSIMERTINIB - Abstract
High interindividual variability (IIV) of the clinical response to epidermal growth factor receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might be related to the IIV in plasma exposure. The aim of this study was to evaluate the exposure–response relationship for toxicity and efficacy of osimertinib in unselected patients with advanced EGFR-mutant NSCLC. This retrospective analysis included 87 patients treated with osimertinib. Exposure–toxicity analysis was performed in the entire cohort and survival analysis only in second-line patients (n = 45). No significant relationship between occurrence of dose-limiting toxicity and plasma exposure was observed in the entire cohort (p = 0.23, n = 86). The median overall survival (OS) was approximately two-fold shorter in the 4th quartile (Q4) of osimertinib trough plasma concentration (>235 ng/mL) than in the Q1–Q3 group (12.2 months [CI95% = 8.0–not reached (NR)] vs. 22.7 months [CI95% = 17.1–34.1]), but the difference was not statistically significant (p = 0.15). To refine this result, the exposure–survival relationship was explored in a cohort of 41 NSCLC patients treated with erlotinib. The Q4 erlotinib exposure group (>1728 ng/mL) exhibited a six-fold shorter median OS than the Q1–Q3 group (4.8 months [CI95% = 3.3-NR] vs. 22.8 months (CI95% = 10.6–37.4), p = 0.00011). These results suggest that high exposure to EGFR inhibitors might be related to worse survival in NSCLC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients.
- Author
-
Minot-This, Marie-Sophie, Boudou-Rouquette, Pascaline, Jouinot, Anne, de Percin, Sixtine, Balakirouchenane, David, Khoudour, Nihel, Tlemsani, Camille, Chauvin, Jonathan, Thomas-Schoemann, Audrey, Goldwasser, François, Blanchet, Benoit, and Alexandre, Jérôme
- Subjects
SARCOMA ,PROGRESSION-free survival ,NEOVASCULARIZATION inhibitors ,LOGISTIC regression analysis ,ODDS ratio - Abstract
Background: Pazopanib (PAZ) is an oral angiogenesis inhibitor approved to treat soft tissue sarcoma (STS) but associated with a large interpatient pharmacokinetic (PK) variability and narrow therapeutic index. We aimed to define the specific threshold of PAZ trough concentration (C
min ) associated with better progression-free survival (PFS) in STS patients. Methods: In this observational study, PAZ Cmin was monitored over the treatment course. For the primary endpoint, the 3-month PFS in STS was analyzed with logistic regression. Second, we performed exposure–overall survival (OS) (Cox model plus Kaplan–Meier analysis/log-rank test) and exposure–toxicity analyses. Results: Ninety-five STS patients were eligible for pharmacokinetic/pharmacodynamic (PK/PD) assessment. In the multivariable analysis, PAZ Cmin < 27 mg/L was independently associated with a risk of progression at 3 months (odds ratio (OR) 4.21, 95% confidence interval (CI) (1.47–12.12), p = 0.008). A higher average of PAZ Cmin over the first 3 months was associated with a higher risk of grade 3–4 toxicities according to the NCI-CTCAE version 5.0 (OR 1.07 per 1 mg/L increase, CI95 (1.02–1.13), p = 0.007). Conclusion: PAZ Cmin ≥ 27 mg/L was independently associated with improved 3-month PFS in STS patients. Pharmacokinetically-guided dosing could be helpful to optimize the clinical management of STS patients in daily clinical practice. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
11. Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients
- Author
-
Tron, Camille, Woillard, Jean-Baptiste, Houssel-Debry, Pauline, David, Véronique, Jezequel, Caroline, Rayar, Michel, Balakirouchenane, David, Blanchet, Benoit, Debord, Jean, Petitcollin, Antoine, Roussel, Mickaël, Verdier, Marie-Clémence, Bellissant, Eric, Lemaitre, Florian, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Pharmacology and Toxicology [Limoges], CHU Limoges, Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation (IPPRITT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Université de Limoges (UNILIM), Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Department of Molecular Genetics and Genomics [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Pharmacokinetics and Pharmacochemistry Department [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Chimie Organique, Médicinale et Extractive et Toxicologie Expérimentale (COMETE - UMR 8638), Université Paris Descartes - Paris 5 (UPD5)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Haematology Laboratory [Rennes], Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Bodescot, Myriam
- Subjects
Male ,Heredity ,ATP Binding Cassette Transporter, Subfamily B ,Genotype ,Physiology ,chemical and pharmacologic phenomena ,Surgical and Invasive Medical Procedures ,Polymorphism, Single Nucleotide ,Tacrolimus ,Molecular Genetics ,Digestive System Procedures ,Medicine and Health Sciences ,Genetics ,Cytochrome P-450 CYP3A ,Humans ,Pharmacokinetics ,Molecular Biology ,Aged ,Pharmacology ,Immunosuppression Therapy ,Transplantation ,Biology and Life Sciences ,Drugs ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,Organ Transplantation ,Hematology ,Middle Aged ,Immunosuppressives ,[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,Body Fluids ,Liver Transplantation ,Pharmacogenomic Testing ,Blood Counts ,stomatognathic diseases ,Genetic Mapping ,Blood ,Pharmacodynamics ,Hematocrit ,Haplotypes ,Pharmacogenetics ,[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Leukocytes, Mononuclear ,Female ,Anatomy ,Immunosuppressive Agents ,Research Article - Abstract
International audience; Tacrolimus (TAC) is the cornerstone of immunosuppressive therapy in liver transplantation. This study aimed at elucidating the interplay between pharmacogenetic determinants of TAC whole blood and intracellular exposures as well as the pharmacokinetic-pharmacodynamic relationship of TAC in both compartments. Complete pharmacokinetic profiles (Predose, and 20 min, 40 min, 1h, 2h, 3h, 4h, 6h, 8h, 12h post drug intake) of twice daily TAC in whole blood and peripheral blood mononuclear cells (PBMC) were collected in 32 liver transplanted patients in the first ten days post transplantation. A non-parametric population pharmacokinetic model was applied to explore TAC pharmacokinetics in blood and PBMC. Concurrently, calcineurin activity was measured in PBMC. Influence of donor and recipient genetic polymorphisms of ABCB1, CYP3A4 and CYP3A5 on TAC exposure was assessed. Recipient ABCB1 polymorphisms 1199G>A could influence TAC whole blood and intracellular exposure (p
- Published
- 2020
12. Pharmacokinetics of Baclofen in a Full-Term Newborn after Intrauterine Exposure: A Case Report.
- Author
-
Balakirouchenane, David, Khoudour, Nihel, Chouchana, Laurent, Chevillard, Lucie, Parat, Sophie, and Declèves, Xavier
- Subjects
- *
NEWBORN infants , *BACLOFEN , *PHARMACOKINETICS , *ADULTS , *LABOR (Obstetrics) - Abstract
Intrauterine exposure to baclofen can lead to syndrome of withdrawal during the first days of the newborn. We report the case of a full-term baby exposed to baclofen during pregnancy. The mother was treated with baclofen 10 mg 4 times daily. Blood samples were collected from the mother before entering labor and from the baby at H0, H11, H31, and H102 after birth to measure baclofen concentrations and monitor its elimination. Baclofen maternal and neonate pharmacokinetics (PK) and placental transfer were assessed using a physiologically based PK model. Baclofen PK in the neonate after birth followed a monoexponential elimination with a half-life of 10 h, 3-fold longer than that in adults. The newborn was monitored for 11 days without experiencing any symptoms of withdrawal. Reducing baclofen dosing regimen of the mother to the lowest and therefore reducing fetal exposure to baclofen is essential. This case reports for the first time the baclofen pharmacokinetic profile in a newborn. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients.
- Author
-
Tron, Camille, Woillard, Jean-Baptiste, Houssel-Debry, Pauline, David, Véronique, Jezequel, Caroline, Rayar, Michel, Balakirouchenane, David, Blanchet, Benoit, Debord, Jean, Petitcollin, Antoine, Roussel, Mickaël, Verdier, Marie-Clémence, Bellissant, Eric, and Lemaitre, Florian
- Subjects
LIVER transplantation ,BLOOD ,BLOOD cells ,GENETIC polymorphisms ,INDIVIDUALIZED medicine - Abstract
Tacrolimus (TAC) is the cornerstone of immunosuppressive therapy in liver transplantation. This study aimed at elucidating the interplay between pharmacogenetic determinants of TAC whole blood and intracellular exposures as well as the pharmacokinetic-pharmacodynamic relationship of TAC in both compartments. Complete pharmacokinetic profiles (Predose, and 20 min, 40 min, 1h, 2h, 3h, 4h, 6h, 8h, 12h post drug intake) of twice daily TAC in whole blood and peripheral blood mononuclear cells (PBMC) were collected in 32 liver transplanted patients in the first ten days post transplantation. A non-parametric population pharmacokinetic model was applied to explore TAC pharmacokinetics in blood and PBMC. Concurrently, calcineurin activity was measured in PBMC. Influence of donor and recipient genetic polymorphisms of ABCB1, CYP3A4 and CYP3A5 on TAC exposure was assessed. Recipient ABCB1 polymorphisms 1199G>A could influence TAC whole blood and intracellular exposure (p<0.05). No association was found between CYP3A4 or CYP3A5 genotypes and TAC whole blood or intracellular concentrations. Finally, intra-PBMC calcineurin activity appeared incompletely inhibited by TAC and less than 50% of patients were expected to achieve intracellular IC
50 concentration (100 pg/millions of cells) at therapeutic whole blood concentration (i.e.: 4–10 ng/mL). Together, these data suggest that personalized medicine regarding TAC therapy might be optimized by ABCB1 pharmacogenetic biomarkers and by monitoring intracellular concentration whereas the relationship between intracellular TAC exposure and pharmacodynamics biomarkers more specific than calcineurin activity should be further investigated. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
14. Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study.
- Author
-
Velev, Maud, Puszkiel, Alicja, Blanchet, Benoit, de Percin, Sixtine, Delanoy, Nicolas, Medioni, Jacques, Gervais, Claire, Balakirouchenane, David, Khoudour, Nihel, Pautier, Patricia, Leary, Alexandra, Ajgal, Zahra, Hirsch, Laure, Goldwasser, François, Alexandre, Jerome, and Beinse, Guillaume
- Subjects
RECEIVER operating characteristic curves ,OVARIAN cancer ,CANCER patients ,OLAPARIB ,LIQUID chromatography ,DRUG monitoring - Abstract
Factors associated with olaparib toxicity remain unknown in ovarian cancer patients. The large inter-individual variability in olaparib pharmacokinetics could contribute to the onset of early significant adverse events (SAE). We aimed to retrospectively analyze the pharmacokinetic/pharmacodynamic relationship for toxicity in ovarian cancer patients from "real life" data. The clinical endpoint was the onset of SAE (grade III/IV toxicity or dose reduction/discontinuation). Plasma olaparib concentration was assayed using liquid chromatography at any time over the dosing interval. Trough concentrations (CminPred) were estimated using a population pharmacokinetic model. The association between toxicity and clinical characteristics or CminPred was assessed by logistic regression and non-parametric statistical tests. Twenty-seven patients were included, among whom 13 (48%) experienced SAE during the first six months of treatment. Olaparib CminPred was the only covariate significantly associated with increased risk of SAE onset (odds ratio = 1.31, 95% CI = [1.10; 1.57], for each additional 1000 ng/mL). The ROC curve identified a threshold of CminPred = 2500 ng/mL for prediction of SAE onset (sensitivity/specificity 0.62 and 1.00, respectively). This study highlights a significant association between olaparib plasma exposure and SAE onset and identified the threshold of 2500 ng/mL trough concentration as potentially useful to guide dose adjustment in ovarian cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma.
- Author
-
Balakirouchenane, David, Guégan, Sarah, Csajka, Chantal, Jouinot, Anne, Heidelberger, Valentine, Puszkiel, Alicja, Zehou, Ouidad, Khoudour, Nihel, Courlet, Perrine, Kramkimel, Nora, Lheure, Coralie, Franck, Nathalie, Huillard, Olivier, Arrondeau, Jennifer, Vidal, Michel, Goldwasser, Francois, Maubec, Eve, Dupin, Nicolas, Aractingi, Selim, and Guidi, Monia
- Subjects
- *
ANTINEOPLASTIC agents , *AGE distribution , *BRAIN tumors , *DRUG monitoring , *DOSE-effect relationship in pharmacology , *DRUG toxicity , *ENZYME inhibitors , *FISHER exact test , *MELANOMA , *METASTASIS , *RISK assessment , *SEX distribution , *SURVIVAL analysis (Biometry) , *TREATMENT effectiveness , *SEVERITY of illness index , *PHARMACODYNAMICS - Abstract
Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics of DAB, hydroxy-dabrafenib (OHD), and TRA in BRAF-mutated patients and to investigate the exposure–response relationship for toxicity and efficacy in metastatic melanoma (MM) patients. Univariate Fisher and Wilcoxon models including drug systemic exposure (area under the plasma concentration curve, AUC) were used to identify prognostic factors for the onset of dose-limiting toxicities (DLT), and Cox models for overall (OS) and progression-free survival (PFS). Seventy-three BRAF-mutated patients were included in pharmacokinetic (n = 424, NONMEM) and 52 in pharmacokinetic/pharmacodynamic analyses. Age and sex were identified as determinants of DAB and OHD clearances (p < 0.01). MM patients experiencing DLT were overexposed to DAB compared to patients without DLT (AUC: 9624 vs. 7485 ng∙h/mL, respectively, p < 0.01). Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥ 2 and plasma ratio AUCOHD/AUCDAB ≥ 1 were independently associated with shorter OS (HR: 6.58 (1.29–33.56); p = 0.023 and 10.61 (2.34–48.15), p = 0.022, respectively). A number of metastatic sites ≥3 and cerebral metastases were associated with shorter PFS (HR = 3.25 (1.11–9.50); p = 0.032 and HR = 1.23 (1.35–10.39), p = 0.011; respectively). TRA plasma exposure was neither associated with toxicity nor efficacy. Our results suggest that early drug monitoring could be helpful to prevent the onset of DLT in MM patients, especially in fragile patients such as the elderly. Regarding efficacy, the clinical benefit to monitor plasma ratio AUCOHD/AUCDAB deserves more investigation in a larger cohort of MM patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.